Serena Williams, a titan of sport and an embodiment of athletic prowess, has openly discussed her use of these medications, specifically a GLP-1 agonist. Her stated aim? To help shed the stigma associated with such treatments. At 43, and after a career marked by 23 Grand Slam titles, she’s certainly no stranger to pushing boundaries. However, post pregnancy, she, like many individuals, found herself struggling with persistent weight. She described viewing this excess weight as an opponent that, despite training five hours a day and rigorous physical activity, she couldn’t conquer through traditional means alone. This led her to try something different, exploring the very medications many of her friends were already using.
Williams emphatically states that this wasn’t a shortcut, having lost 31lb (14kg) over eight months with considerable effort. However, it’s worth noting the timing of her transparency, coinciding with her role as a spokesperson for Ro, a company that facilitates access to GLP-1 brands like Wegovy and Zepbound (known as Mounjaro in the UK), and her husband’s investment in the firm. This commercial aspect, while transparent, naturally invites scrutiny.
Despite these commercial ties and the inherent discussion around potential side effects, her candour resonates deeply. Caleb Luna, Assistant Professor of Feminist Studies at the University of California, hails Williams’s revelation as a breakthrough. They argue it directly challenges the notion that weight loss achieved through medication is the easy way out, dismantling stereotypes that these drugs are solely for lazy and incompetent individuals. In this respect, it potentially fosters a more understanding environment for those considering or using these treatments.
However, Luna also expresses a degree of sadness and concern, suggesting that such a revelation, even from an athlete of Williams’s calibre, inadvertently belittles hard work and dedication, shifting the focus disproportionately towards appearance and societal pressures. It just shows how all those accomplishments can be undermined by body size, they muse, adding that scarily, weight loss seems to outshine all those record-breaking achievements. This highlights a crucial tension: the legitimate medical need versus the pervasive societal pressure to conform to specific body ideals.
Williams’s physical appearance and weight have been under public scrutiny throughout her career, underscoring that the pressure to meet societal expectations remains, irrespective of professional success. She joins a growing list of public figures, including Oprah Winfrey, Whoopi Goldberg, and Kelly Clarkson, who have openly discussed their use of GLP-1 agonists as tools for weight management, often alongside exercise and dietary changes.
For Williams, who retired from professional tennis in 2022, the goal has been to reach her healthy weight since the birth of her second child, Adira. She felt her body was missing something and struggled to reach a comfortable weight despite intense training. Dr. Claire Madigan, a senior research associate in behavioural medicine at Loughborough University, highlights that elite athletes often face unique challenges in weight management post retirement, accustomed to high caloric intake during their sporting careers. Dr. Madigan commends Williams for emphasising that her weight loss wasn’t solely due to the drug but required continued focus on diet and physical activity, and for speaking openly about the difficulties of postpartum weight loss.
Conversely, Dr. Madigan raises concerns that Williams’s message might inadvertently demotivate some, given the expense of these drugs and the perception that even an elite athlete with access to extensive resources (gyms, nutritionists, time) required medication. Furthermore, the public discourse around Williams’s announcement may not have adequately addressed the potential side effects of GLP-1s, which can include common gastrointestinal issues like vomiting and diarrhoea, and in rarer instances, gallbladder and kidney problems. Williams, for her part, reports no side effects and notes health benefits such as improved joint health and excellent blood sugar levels.
Ultimately, Serena Williams’s public discussion opens a vital dialogue. While the clinical efficacy of GLP-1 agonists in obesity management is well documented, the ethical, social, and psychological ramifications of their widespread use, particularly in a society already burdened by body image pressures, warrant careful consideration. It’s a complex interplay between medical advancement, individual choice, and societal expectation, and Williams’s story undoubtedly adds a significant voice to this unfolding narrative. She is, after all, smashing her own records by training for a half marathon, running “farther than I ever have.”
